Expert Interview
Exploring the Factor XI landscape with a focus on NOVO/Anthos' abelacimab and Regeneron's REGN9933/7508
Ticker(s): NVO, REGN, Anthos TherapeuticsInstitution: University of Utah
- Associate Professor in the Division of Hematology and Hematologic Malignancies at the University of Utah.
- Research focused on complications affecting people with congenital bleeding disorders, specifically persons with hemophilia with inhibitors and pregnant women with bleeding disorders; clinical interest lies in the field of hemostasis and thrombosis.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
